NEXI-002 is an autologous T cell therapy that consists of T cell populations directed against multiple tumor-relevant antigen targets: WT1, CD138, CS1 and NY-ESO-1.
You can give us a call at (888) 828-2206 or create your account to add this treatment to your list of favorites. We'll send you alerts when this treatment is updated.